أعرض في EDS

Primary prevention of cardiovascular disease in patients with systemic lupus erythematosus: case series and literature review

التفاصيل البيبلوغرافية
العنوان: Primary prevention of cardiovascular disease in patients with systemic lupus erythematosus: case series and literature review
المؤلفون: FASANO, Silvia, Margiotta, D. P, Navarini, L, Pierro, L, Pantano, I, RICCARDI, Antonietta, Afeltra, A, VALENTINI, Gabriele, FASANO Serena
المساهمون: Fasano, S., Margiotta, D. P., Navarini, L., Pierro, L., Pantano, I., Riccardi, A., Afeltra, A., Valentini, G., Fasano, Silvia, Margiotta, D. P, Navarini, L, Pierro, L, Pantano, I, Riccardi, Antonietta, Afeltra, A, Valentini, Gabriele, Fasano, Serena
المصدر: Lupus. 26(14)
سنة النشر: 2017
مصطلحات موضوعية: cardiovascular risk, Adult, Male, medicine.medical_specialty, Multivariate analysis, Systemic lupus erythematosu, Disease, 030204 cardiovascular system & hematology, statins, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Risk Factors, Cardiovascular Disease, Primary prevention, Internal medicine, medicine, Humans, Lupus Erythematosus, Systemic, Antiphospholipid antibody positivity, 030203 arthritis & rheumatology, Aspirin, business.industry, Proportional hazards model, Hazard ratio, statin, Hydroxychloroquine, Primary Prevention, Cardiovascular Diseases, Immunology, Antibodies, Antiphospholipid, Female, Hydroxymethylglutaryl-CoA Reductase Inhibitor, Hydroxymethylglutaryl-CoA Reductase Inhibitors, business, Human, medicine.drug
الوصف: Background Systemic lupus erythematosus is associated with an increased risk of cardiovascular disease. Low-dose aspirin, hydroxychloroquine and statins have been suggested to play a prophylactic role of cardiovascular events. This study is devoted to reviewing the literature on the topic and assessing the effects of these drugs in preventing a first cardiovascular event in a two-centre Italian series. Methods A PubMed search on cardiovascular prevention in systemic lupus erythematosus was performed. Moreover, systemic lupus erythematosus patients admitted to two centres from 2000-2015, who at admission had not experienced any cardiovascular event, were investigated. Aspirin, hydroxychloroquine and statin use, and the occurrence of any cardiovascular event, were recorded at each visit. Kaplan-Meier and Cox regression analyses were performed to evaluate the role of traditional, disease-related cardiovascular risk factors and of each of the three drugs in the occurrence of new cardiovascular events. Results The literature search produced conflicting results. Two hundred and ninety-one systemic lupus erythematosus patients were included in the study and followed for a median of eight years. During follow-up, 16 cardiovascular events occurred. At multivariate analysis, taking aspirin (hazard ratio: 0.24) and hydroxychloroquine for more than five years (hazard ratio: 0.27) reduced, while antiphospholipid antibody positivity (hazard ratio: 4.32) increased, the risk of a first cardiovascular event. No effect of statins emerged. Conclusion Our study confirms an additive role of aspirin and hydroxychloroquine in the primary prophylaxis of cardiovascular events in Italian patients with systemic lupus erythematosus. The lack of any detected effect in previous reports may depend on the design of studies and their short follow-up period. Background: Systemic lupus erythematosus is associated with an increased risk of cardiovascular disease. Low-dose aspirin, hydroxychloroquine and statins have been suggested to play a prophylactic role of cardiovascular events. This study is devoted to reviewing the literature on the topic and assessing the effects of these drugs in preventing a first cardiovascular event in a two-centre Italian series. Methods: A PubMed search on cardiovascular prevention in systemic lupus erythematosus was performed. Moreover, systemic lupus erythematosus patients admitted to two centres from 2000–2015, who at admission had not experienced any cardiovascular event, were investigated. Aspirin, hydroxychloroquine and statin use, and the occurrence of any cardiovascular event, were recorded at each visit. Kaplan-Meier and Cox regression analyses were performed to evaluate the role of traditional, disease-related cardiovascular risk factors and of each of the three drugs in the occurrence of new cardiovascular events. Results: The literature search produced conflicting results. Two hundred and ninety-one systemic lupus erythematosus patients were included in the study and followed for a median of eight years. During follow-up, 16 cardiovascular events occurred. At multivariate analysis, taking aspirin (hazard ratio: 0.24) and hydroxychloroquine for more than five years (hazard ratio: 0.27) reduced, while antiphospholipid antibody positivity (hazard ratio: 4.32) increased, the risk of a first cardiovascular event. No effect of statins emerged. Conclusion: Our study confirms an additive role of aspirin and hydroxychloroquine in the primary prophylaxis of cardiovascular events in Italian patients with systemic lupus erythematosus. The lack of any detected effect in previous reports may depend on the design of studies and their short follow-up period.
تدمد: 1477-0962
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01496bfe37587a3ffd03a81ceab09a82
https://pubmed.ncbi.nlm.nih.gov/28786768
Rights: CLOSED
رقم الانضمام: edsair.doi.dedup.....01496bfe37587a3ffd03a81ceab09a82
قاعدة البيانات: OpenAIRE
ResultId 1
Header edsair
OpenAIRE
edsair.doi.dedup.....01496bfe37587a3ffd03a81ceab09a82
808
3

unknown
807.649719238281
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....01496bfe37587a3ffd03a81ceab09a82&custid=s6537998&authtype=sso
FullText Array ( [Availability] => 0 )
Array ( [0] => Array ( [Url] => https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01496bfe37587a3ffd03a81ceab09a82# [Name] => EDS - OpenAIRE [Category] => fullText [Text] => View record in OpenAIRE [MouseOverText] => View record in OpenAIRE ) )
Items Array ( [Name] => Title [Label] => Title [Group] => Ti [Data] => Primary prevention of cardiovascular disease in patients with systemic lupus erythematosus: case series and literature review )
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22FASANO%2C+Silvia%22">FASANO, Silvia</searchLink><br /><searchLink fieldCode="AR" term="%22Margiotta%2C+D%2E+P%22">Margiotta, D. P</searchLink><br /><searchLink fieldCode="AR" term="%22Navarini%2C+L%22">Navarini, L</searchLink><br /><searchLink fieldCode="AR" term="%22Pierro%2C+L%22">Pierro, L</searchLink><br /><searchLink fieldCode="AR" term="%22Pantano%2C+I%22">Pantano, I</searchLink><br /><searchLink fieldCode="AR" term="%22RICCARDI%2C+Antonietta%22">RICCARDI, Antonietta</searchLink><br /><searchLink fieldCode="AR" term="%22Afeltra%2C+A%22">Afeltra, A</searchLink><br /><searchLink fieldCode="AR" term="%22VALENTINI%2C+Gabriele%22">VALENTINI, Gabriele</searchLink><br /><searchLink fieldCode="AR" term="%22FASANO+Serena%22">FASANO Serena</searchLink> )
Array ( [Name] => Author [Label] => Contributors [Group] => Au [Data] => Fasano, S.<br />Margiotta, D. P.<br />Navarini, L.<br />Pierro, L.<br />Pantano, I.<br />Riccardi, A.<br />Afeltra, A.<br />Valentini, G.<br />Fasano, Silvia<br />Margiotta, D. P<br />Navarini, L<br />Pierro, L<br />Pantano, I<br />Riccardi, Antonietta<br />Afeltra, A<br />Valentini, Gabriele<br />Fasano, Serena )
Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => <i>Lupus</i>. 26(14) )
Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2017 )
Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22cardiovascular+risk%22">cardiovascular risk</searchLink><br /><searchLink fieldCode="DE" term="%22Adult%22">Adult</searchLink><br /><searchLink fieldCode="DE" term="%22Male%22">Male</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Emedical%5Fspecialty%22">medicine.medical_specialty</searchLink><br /><searchLink fieldCode="DE" term="%22Multivariate+analysis%22">Multivariate analysis</searchLink><br /><searchLink fieldCode="DE" term="%22Systemic+lupus+erythematosu%22">Systemic lupus erythematosu</searchLink><br /><searchLink fieldCode="DE" term="%22Disease%22">Disease</searchLink><br /><searchLink fieldCode="DE" term="%22030204+cardiovascular+system+%26+hematology%22">030204 cardiovascular system & hematology</searchLink><br /><searchLink fieldCode="DE" term="%22statins%22">statins</searchLink><br /><searchLink fieldCode="DE" term="%2203+medical+and+health+sciences%22">03 medical and health sciences</searchLink><br /><searchLink fieldCode="DE" term="%220302+clinical+medicine%22">0302 clinical medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Rheumatology%22">Rheumatology</searchLink><br /><searchLink fieldCode="DE" term="%22Risk+Factors%22">Risk Factors</searchLink><br /><searchLink fieldCode="DE" term="%22Cardiovascular+Disease%22">Cardiovascular Disease</searchLink><br /><searchLink fieldCode="DE" term="%22Primary+prevention%22">Primary prevention</searchLink><br /><searchLink fieldCode="DE" term="%22Internal+medicine%22">Internal medicine</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%22">medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Humans%22">Humans</searchLink><br /><searchLink fieldCode="DE" term="%22Lupus+Erythematosus%2C+Systemic%22">Lupus Erythematosus, Systemic</searchLink><br /><searchLink fieldCode="DE" term="%22Antiphospholipid+antibody+positivity%22">Antiphospholipid antibody positivity</searchLink><br /><searchLink fieldCode="DE" term="%22030203+arthritis+%26+rheumatology%22">030203 arthritis & rheumatology</searchLink><br /><searchLink fieldCode="DE" term="%22Aspirin%22">Aspirin</searchLink><br /><searchLink fieldCode="DE" term="%22business%2Eindustry%22">business.industry</searchLink><br /><searchLink fieldCode="DE" term="%22Proportional+hazards+model%22">Proportional hazards model</searchLink><br /><searchLink fieldCode="DE" term="%22Hazard+ratio%22">Hazard ratio</searchLink><br /><searchLink fieldCode="DE" term="%22statin%22">statin</searchLink><br /><searchLink fieldCode="DE" term="%22Hydroxychloroquine%22">Hydroxychloroquine</searchLink><br /><searchLink fieldCode="DE" term="%22Primary+Prevention%22">Primary Prevention</searchLink><br /><searchLink fieldCode="DE" term="%22Cardiovascular+Diseases%22">Cardiovascular Diseases</searchLink><br /><searchLink fieldCode="DE" term="%22Immunology%22">Immunology</searchLink><br /><searchLink fieldCode="DE" term="%22Antibodies%2C+Antiphospholipid%22">Antibodies, Antiphospholipid</searchLink><br /><searchLink fieldCode="DE" term="%22Female%22">Female</searchLink><br /><searchLink fieldCode="DE" term="%22Hydroxymethylglutaryl-CoA+Reductase+Inhibitor%22">Hydroxymethylglutaryl-CoA Reductase Inhibitor</searchLink><br /><searchLink fieldCode="DE" term="%22Hydroxymethylglutaryl-CoA+Reductase+Inhibitors%22">Hydroxymethylglutaryl-CoA Reductase Inhibitors</searchLink><br /><searchLink fieldCode="DE" term="%22business%22">business</searchLink><br /><searchLink fieldCode="DE" term="%22Human%22">Human</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Edrug%22">medicine.drug</searchLink> )
Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Background Systemic lupus erythematosus is associated with an increased risk of cardiovascular disease. Low-dose aspirin, hydroxychloroquine and statins have been suggested to play a prophylactic role of cardiovascular events. This study is devoted to reviewing the literature on the topic and assessing the effects of these drugs in preventing a first cardiovascular event in a two-centre Italian series. Methods A PubMed search on cardiovascular prevention in systemic lupus erythematosus was performed. Moreover, systemic lupus erythematosus patients admitted to two centres from 2000-2015, who at admission had not experienced any cardiovascular event, were investigated. Aspirin, hydroxychloroquine and statin use, and the occurrence of any cardiovascular event, were recorded at each visit. Kaplan-Meier and Cox regression analyses were performed to evaluate the role of traditional, disease-related cardiovascular risk factors and of each of the three drugs in the occurrence of new cardiovascular events. Results The literature search produced conflicting results. Two hundred and ninety-one systemic lupus erythematosus patients were included in the study and followed for a median of eight years. During follow-up, 16 cardiovascular events occurred. At multivariate analysis, taking aspirin (hazard ratio: 0.24) and hydroxychloroquine for more than five years (hazard ratio: 0.27) reduced, while antiphospholipid antibody positivity (hazard ratio: 4.32) increased, the risk of a first cardiovascular event. No effect of statins emerged. Conclusion Our study confirms an additive role of aspirin and hydroxychloroquine in the primary prophylaxis of cardiovascular events in Italian patients with systemic lupus erythematosus. The lack of any detected effect in previous reports may depend on the design of studies and their short follow-up period. Background: Systemic lupus erythematosus is associated with an increased risk of cardiovascular disease. Low-dose aspirin, hydroxychloroquine and statins have been suggested to play a prophylactic role of cardiovascular events. This study is devoted to reviewing the literature on the topic and assessing the effects of these drugs in preventing a first cardiovascular event in a two-centre Italian series. Methods: A PubMed search on cardiovascular prevention in systemic lupus erythematosus was performed. Moreover, systemic lupus erythematosus patients admitted to two centres from 2000–2015, who at admission had not experienced any cardiovascular event, were investigated. Aspirin, hydroxychloroquine and statin use, and the occurrence of any cardiovascular event, were recorded at each visit. Kaplan-Meier and Cox regression analyses were performed to evaluate the role of traditional, disease-related cardiovascular risk factors and of each of the three drugs in the occurrence of new cardiovascular events. Results: The literature search produced conflicting results. Two hundred and ninety-one systemic lupus erythematosus patients were included in the study and followed for a median of eight years. During follow-up, 16 cardiovascular events occurred. At multivariate analysis, taking aspirin (hazard ratio: 0.24) and hydroxychloroquine for more than five years (hazard ratio: 0.27) reduced, while antiphospholipid antibody positivity (hazard ratio: 4.32) increased, the risk of a first cardiovascular event. No effect of statins emerged. Conclusion: Our study confirms an additive role of aspirin and hydroxychloroquine in the primary prophylaxis of cardiovascular events in Italian patients with systemic lupus erythematosus. The lack of any detected effect in previous reports may depend on the design of studies and their short follow-up period. )
Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 1477-0962 )
Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01496bfe37587a3ffd03a81ceab09a82" linkWindow="_blank">https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01496bfe37587a3ffd03a81ceab09a82</link><br /><link linkTarget="URL" linkTerm="https://pubmed.ncbi.nlm.nih.gov/28786768" linkWindow="_blank">https://pubmed.ncbi.nlm.nih.gov/28786768</link> )
Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => CLOSED )
Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsair.doi.dedup.....01496bfe37587a3ffd03a81ceab09a82 )
RecordInfo Array ( [BibEntity] => Array ( [Languages] => Array ( [0] => Array ( [Text] => Undetermined ) ) [Subjects] => Array ( [0] => Array ( [SubjectFull] => cardiovascular risk [Type] => general ) [1] => Array ( [SubjectFull] => Adult [Type] => general ) [2] => Array ( [SubjectFull] => Male [Type] => general ) [3] => Array ( [SubjectFull] => medicine.medical_specialty [Type] => general ) [4] => Array ( [SubjectFull] => Multivariate analysis [Type] => general ) [5] => Array ( [SubjectFull] => Systemic lupus erythematosu [Type] => general ) [6] => Array ( [SubjectFull] => Disease [Type] => general ) [7] => Array ( [SubjectFull] => 030204 cardiovascular system & hematology [Type] => general ) [8] => Array ( [SubjectFull] => statins [Type] => general ) [9] => Array ( [SubjectFull] => 03 medical and health sciences [Type] => general ) [10] => Array ( [SubjectFull] => 0302 clinical medicine [Type] => general ) [11] => Array ( [SubjectFull] => Rheumatology [Type] => general ) [12] => Array ( [SubjectFull] => Risk Factors [Type] => general ) [13] => Array ( [SubjectFull] => Cardiovascular Disease [Type] => general ) [14] => Array ( [SubjectFull] => Primary prevention [Type] => general ) [15] => Array ( [SubjectFull] => Internal medicine [Type] => general ) [16] => Array ( [SubjectFull] => medicine [Type] => general ) [17] => Array ( [SubjectFull] => Humans [Type] => general ) [18] => Array ( [SubjectFull] => Lupus Erythematosus, Systemic [Type] => general ) [19] => Array ( [SubjectFull] => Antiphospholipid antibody positivity [Type] => general ) [20] => Array ( [SubjectFull] => 030203 arthritis & rheumatology [Type] => general ) [21] => Array ( [SubjectFull] => Aspirin [Type] => general ) [22] => Array ( [SubjectFull] => business.industry [Type] => general ) [23] => Array ( [SubjectFull] => Proportional hazards model [Type] => general ) [24] => Array ( [SubjectFull] => Hazard ratio [Type] => general ) [25] => Array ( [SubjectFull] => statin [Type] => general ) [26] => Array ( [SubjectFull] => Hydroxychloroquine [Type] => general ) [27] => Array ( [SubjectFull] => Primary Prevention [Type] => general ) [28] => Array ( [SubjectFull] => Cardiovascular Diseases [Type] => general ) [29] => Array ( [SubjectFull] => Immunology [Type] => general ) [30] => Array ( [SubjectFull] => Antibodies, Antiphospholipid [Type] => general ) [31] => Array ( [SubjectFull] => Female [Type] => general ) [32] => Array ( [SubjectFull] => Hydroxymethylglutaryl-CoA Reductase Inhibitor [Type] => general ) [33] => Array ( [SubjectFull] => Hydroxymethylglutaryl-CoA Reductase Inhibitors [Type] => general ) [34] => Array ( [SubjectFull] => business [Type] => general ) [35] => Array ( [SubjectFull] => Human [Type] => general ) [36] => Array ( [SubjectFull] => medicine.drug [Type] => general ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => Primary prevention of cardiovascular disease in patients with systemic lupus erythematosus: case series and literature review [Type] => main ) ) ) [BibRelationships] => Array ( [HasContributorRelationships] => Array ( [0] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => FASANO, Silvia ) ) ) [1] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Margiotta, D. P ) ) ) [2] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Navarini, L ) ) ) [3] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Pierro, L ) ) ) [4] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Pantano, I ) ) ) [5] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => RICCARDI, Antonietta ) ) ) [6] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Afeltra, A ) ) ) [7] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => VALENTINI, Gabriele ) ) ) [8] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => FASANO Serena ) ) ) [9] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Fasano, S. ) ) ) [10] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Margiotta, D. P. ) ) ) [11] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Navarini, L. ) ) ) [12] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Pierro, L. ) ) ) [13] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Pantano, I. ) ) ) [14] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Riccardi, A. ) ) ) [15] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Afeltra, A. ) ) ) [16] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Valentini, G. ) ) ) [17] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Fasano, Silvia ) ) ) [18] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Margiotta, D. P ) ) ) [19] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Navarini, L ) ) ) [20] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Pierro, L ) ) ) [21] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Pantano, I ) ) ) [22] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Riccardi, Antonietta ) ) ) [23] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Afeltra, A ) ) ) [24] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Valentini, Gabriele ) ) ) [25] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Fasano, Serena ) ) ) ) [IsPartOfRelationships] => Array ( [0] => Array ( [BibEntity] => Array ( [Dates] => Array ( [0] => Array ( [D] => 09 [M] => 08 [Type] => published [Y] => 2017 ) ) [Identifiers] => Array ( [0] => Array ( [Type] => issn-print [Value] => 14770962 ) [1] => Array ( [Type] => issn-locals [Value] => edsair ) ) [Numbering] => Array ( [0] => Array ( [Type] => volume [Value] => 26 ) [1] => Array ( [Type] => issue [Value] => 14 ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => Lupus [Type] => main ) ) ) ) ) ) )
IllustrationInfo